Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CRS3123 in Healthy Adults
NCT02106338Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of crs-3123 in Clostridioides difficile infection (CDI) (3 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Sequential review of reported adverse events, Changes from baseline in key ECG findings and 5 more. Started Jun 2014; status: completed.
02
Drugs
crs-3123
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT02106338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02106338.